Integrated Bioprocessing Environment for Understanding, Automating and Controlling Protein Quality Attributes
Ongoing work at Bend Research is focused on developing and implementing a process-development methodology that applies state-of-the-art automated sampling technology and on-line and at-line cell-state monitoring technologies-novel and existing-to bioreactor processes. This methodology couples these tools with applied mathematics, data-integration techniques, and an understanding of bioreactor and biologic processes. Ultimately, this methodology offers an improved way to tune and manage cell and protein production processes by optimizing bioreactor processes using real-time data-integration technologies.
The goal of the work at Bend Research is to develop a solutions-based client offering focused on optimizing product quality while streamlining R&D, pilot-scale, and commercial process definition. As well, we are using modeling technologies with a focus on optimizing or maintaining product quality across manufacturing sites and scales. The focus of internal and external research programs has largely been driven by existing and anticipated industry interests and challenges.
Ongoing work around the optimization of bioreactor processes is focused on understanding variables that impact bioreactor productivity, developing predictive models around these variables of interest and defining processes to improve bioreactor performance. The development of robust predictive models around key variables of interest requires the extraction and rapid analysis of large quantities of bioreactor data during model manufacturing fed batch or perfusion runs in order to capture cellular dynamic and steady state performance data. Automated sampling hardware and data curation and storage tools have been developed to streamline this process.
This webinar describes efforts at Bend Research to develop integrated biotherapeutic manufacturing hardware and software technologies to reduce risk and optimize our clients' fed-batch and perfusion processes.
Presented by
Jeffrey Breit, Ph.D.,
Director
Jeffrey Breit is a Director at Bend Research Inc., where he works in the fields of biotherapeutic drug development, inhalation drug delivery and formulation technologies. He has worked at Bend Research for 7 years.
Dr. Breit earned his Ph.D. in Pharmacology from the University of South Alabama, while working in the Center for Lung Biology. His doctoral work focused on defining genetic and molecular signaling processes involved in pulmonary disease. Dr. Breit performed his postdoctoral work at Roche Pharmaceuticals in Palo Alto, California, where he researched the genetics of complex disease states.
Brandon Downey,
Technical Group Leader
Brandon Downey is a Research Chemical Engineer and Technical Group Leader at Bend Research, where he works on new technology development programs. His primary areas of expertise and responsibility include the development, scale-up, and integration of new manufacturing technologies into biotherapeutic production processes with the aim of obtaining better cell- and product-based process guidance. He earned his BS in Chemical Engineering from the University of Colorado, Boulder.
